Authored By: B. V Waghmare

Wednesday, April 5, 2023

How to deal with Recurrent infection serge of corona virus.

How to deal with Recurrent infection serge of corona virus.

Last years in 2020 and 2021 we have faced lock down to protect ourselves from corona virus and its life threatening infection. Many of us went through vaccination and even after vaccination lives were lost due corona infection.

Corona infection acts on the blood and blood vessels, triggering interleukin flair that caused damage to lungs tissue and due to embolism, and subsequent events deaths occurred.

Again it is found that after gap of almost one and half years after successful defeating omicron variant serge again the corona virus infection cases are increasing.

In a latest finding in a research conducted by national institute of health it is found that the person infected with corona virus develop several defects so that the other disease overweighs on the health conditions.

The vaccines are found to produce lesser protective effect in person with earlier infection history and has not received any vaccination. In the study it is found that person who are never infected in them vaccines produced strong protective effect, compared to the person who was previously infected with corona virus. (reference 1)

The person affected with diabetes and higher cholesterol are at high risk from the current serge of corona virus.

Therefore, in order to survive the newer corona infection Yoga Practices should be adapted and practiced daily basis, yoga has found to strengthen immunity.

Treatment for COVID 19, due to the increased number of Omicron (B.1.1.529)   Variants of concern. Reference (2)

In Feb 2023 The National Institute of Health of the United States has published a guideline for providing Treatment for COVID 19, due to the increased number of Omicron (B.1.1.529)   Variants of concern.

The guideline is an eye opener, when NIH mentioned in it that the recently developed monoclonal antibodies treatment for treatment of SARS-COV-2 may not be effective against the Omicron (B.1.1.529).Therefore it has advised in its guideline that doctors should also give remdesavir intravenous dosage to out patients as well, the use of remedisavir was limited to hospitalized patients, while NIH recommend to make use of the remedisavir in outpatient as well along with  NIH in its guideline has also recommended use of only one monoclonal antibody Sotrovimab 500 mg Intravenous as a single infusion (AIIa) immediately within 10 days of symptoms onset.

1.Sotrovimab 500 mg Intravenous as a single infusion (AIIa) immediately and within 10 days of symptom onset.

2. Remdesivir 200 mg intravenous on day 1, then 100 mg once daily on Days 2 and 3 (BIIa) initiated as soon as possible and within 7 days of symptom onset.

Remedesivir intravenous injection requires for three consecutive days therefore it's one of the concerns for outpatients.  

Due to the greater variation in spike protein due to variation in gene sequence the antibodies which were developed with earlier sequence viz bamlanivimab plus etesevimab and casirivimab plus imdevimab, may not be effective against the Omicron (B.1.1.529). Therefore, if at all someone makes use of them, it should be kept in mind that they may not work.

Reference:

(1) Pharma Times

(1) https://www.nih.gov/news-events/news-releases/sars-cov-2-infection-weakens-immune-cell-response-vaccination

(2) https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/

No comments: